ConductScience.org, home

Paper32197856

Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes.

Rittberg R and 5 others. Clin Lung Cancer, 2020. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes. Papers, record 32197856. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32197856

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes.
PubMed
Journal
Clin Lung Cancer
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
0.73
iCite
Revised in PubMed
2021-10-11
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rittberg RRebekah
2Green SSusan
3Aquin TTrevor
4Bucher OOliver
5Banerji SShantanu
6Dawe DEDavid E

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
HospitalizationMajor topic
Lung NeoplasmsMajor topic
Small Cell Lung CarcinomaMajor topic
Aged
Carboplatin
Etoposide
Female
Follow-Up Studies
Humans
Male
Prognosis
Retrospective Studies
Survival Rate

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42505190Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive-Stage Small-Cell Lung Cancer.Curr Oncol2026https://conductscience.org/library/papers/42505190PubMed
42258320Cancer Chemoimmunotherapy: Time Will Tell.Cancer Immunol Res2026https://conductscience.org/library/papers/42258320PubMed
40702109Spatial transcriptomics reveals macrophage domestication by epithelial cells promotes immunotherapy resistance in small cell lung cancer.NPJ Precis Oncol2025https://conductscience.org/library/papers/40702109PubMed
40618113The combination of chemotherapy and immune checkpoint inhibitors in recurrent extensive-stage small cell lung cancer: a case report.J Cardiothorac Surg2025https://conductscience.org/library/papers/40618113PubMed
40529760A SEER prognostic nomogram analysis for extensive-stage small cell lung cancer: comparing the immune checkpoint inhibitors (ICIs) and non-ICIs eras.J Thorac Dis2025https://conductscience.org/library/papers/40529760PubMed
38487532The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.Front Immunol2024https://conductscience.org/library/papers/38487532PubMed
38125937Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada.Front Oncol2023https://conductscience.org/library/papers/38125937PubMed
37795434Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study.Front Oncol2023https://conductscience.org/library/papers/37795434PubMed
36547179Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.Curr Oncol2022https://conductscience.org/library/papers/36547179PubMed
36532013Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.Front Immunol2022https://conductscience.org/library/papers/36532013PubMed
36185266Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer.Front Oncol2022https://conductscience.org/library/papers/36185266PubMed
35454916Baseline Electrocardiographic and Echocardiographic Assessment May Help Predict Survival in Lung Cancer Patients-A Prospective Cardio-Oncology Study.Cancers (Basel)2022https://conductscience.org/library/papers/35454916PubMed
34436036Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada.Curr Oncol2021https://conductscience.org/library/papers/34436036PubMed
34295688First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis.Transl Lung Cancer Res2021https://conductscience.org/library/papers/34295688PubMed
34046100Quality of Life and Psychological Distress of Lung Cancer Patients Undergoing Chemotherapy.World J Oncol2021https://conductscience.org/library/papers/34046100PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32197856

GET https://conductscience.org/api/papers/v1/32197856/authors